Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer (Q78392743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

title

Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference

10

Yuman Fong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

author name string

Joseph J Bennett

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Keith A Delman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Bryan M Burt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Adam Mariotti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Sandeep Malhotra

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Jonathan Zager

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Henrik Petrowsky

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Stephen Mastorides

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Howard Federoff

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

publication date

1 November 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

page(s)

935-945

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12386832%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700510

14 December 2019

exact match

0 references

cites work

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Reduction of Ribonucleotides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

The development of gene therapy for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Initial description of a tumor enhancing activity produced by murine splenocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Characterization of a viable, noninverting herpes simplex virus 1 genome derived by insertion and deletion of sequences at the junction of components L and S.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021

Blood flow and leukocyte adhesiveness are reduced in the microcirculation of a peritoneal disseminated colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700510

7 January 2021